Corrigendum to 'Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies': [ESMO Open Volume 11, Issue 7, July 2026, 107706].

Kim JW, Park YH, Lee S, Ahn HK, Bae J, Park S, Chae H, Kim JH, Lee KH, Kim MH, Lee KE, Kang MJ, Park IH, Chae YS, Lee GW, Park KU, Lee EM, Park JH, Kim JE, Kim HJ, Kim TH, Oh SY, Ko S, Byun JH, Ha JY, Kwon JH, Lee S, Choi JY, Jung JY, Park KH

Open source

DOI: 10.1016/j.esmoop.2026.108527
Published: 2026 Sep
Container: ESMO open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2026.108527,
  title = {Corrigendum to 'Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies': [ESMO Open Volume 11, Issue 7, July 2026, 107706].},
  author = {Kim JW and Park YH and Lee S and Ahn HK and Bae J and Park S and Chae H and Kim JH and Lee KH and Kim MH and Lee KE and Kang MJ and Park IH and Chae YS and Lee GW and Park KU and Lee EM and Park JH and Kim JE and Kim HJ and Kim TH and Oh SY and Ko S and Byun JH and Ha JY and Kwon JH and Lee S and Choi JY and Jung JY and Park KH},
  year = {2026},
  journal = {ESMO open},
  doi = {10.1016/j.esmoop.2026.108527},
  url = {https://doi.org/10.1016/j.esmoop.2026.108527}
}

RIS

TY  - JOUR
TI  - Corrigendum to 'Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies': [ESMO Open Volume 11, Issue 7, July 2026, 107706].
AU  - Kim JW
AU  - Park YH
AU  - Lee S
AU  - Ahn HK
AU  - Bae J
AU  - Park S
AU  - Chae H
AU  - Kim JH
AU  - Lee KH
AU  - Kim MH
AU  - Lee KE
AU  - Kang MJ
AU  - Park IH
AU  - Chae YS
AU  - Lee GW
AU  - Park KU
AU  - Lee EM
AU  - Park JH
AU  - Kim JE
AU  - Kim HJ
AU  - Kim TH
AU  - Oh SY
AU  - Ko S
AU  - Byun JH
AU  - Ha JY
AU  - Kwon JH
AU  - Lee S
AU  - Choi JY
AU  - Jung JY
AU  - Park KH
PY  - 2026
JO  - ESMO open
DO  - 10.1016/j.esmoop.2026.108527
UR  - https://doi.org/10.1016/j.esmoop.2026.108527
ER  -

APA

JW, K., YH, P., S, L., HK, A., J, B., S, P., H, C., JH, K., KH, L., MH, K., KE, L., MJ, K., IH, P., YS, C., GW, L., KU, P., EM, L., JH, P., JE, K., HJ, K., TH, K., SY, O., S, K., JH, B., JY, H., JH, K., S, L., JY, C., JY, J., & KH, P. (2026). Corrigendum to 'Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies': [ESMO Open Volume 11, Issue 7, July 2026, 107706].. ESMO open. https://doi.org/10.1016/j.esmoop.2026.108527

Source records

pubmed · retrieved 2026-09-26T13:13:20.702Z